I have stayed away from Endo International (NASDAQ:ENDP)
I have stayed away from Endo International (NASDAQ:ENDP) for multiple reasons (which has been smart) but that ended today when I bought at $11.56. This trade is verified by Verified Investing, a website that tracks every trade I take, allowing investors to follow my exact entries and exits. I took note of large block buys on Endo International intra-day and a strong uptick in volume. This told me there was a potential bottom and strong institutional accumulation under way. It can often can precede big news. In other words the big boys know before the average investor. In addition, I saw Endo International hitting huge support spanning all the way back to 2001-2002 at $11.00-$11.50. Based on their portfolio of products and revenue, these valuation levels are somewhat attractive. When you add in the other factors mentioned earlier to Endo International, I just had to buy some. I kept my position somewhat small to mitigate risk, but the stock is already proving profitable, now trading close to $12.00. The upside target is $16.00, a 35% profit.
Investors and traders buy Endo International on stock chart
Endo International plc (ENDPQ) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Albion Enterprise VCT PLC Enhances Its Equity Portfolio Albion Enterprise VCT PLC (LSE: AAEV) has recently made a significant move to bolster its equity by issuing new shares. This decision aligns with the company’s commitment to expanding its capital while providing opportunities for shareholders through its Dividend Reinvestment Scheme. Details of the New Share...
Continue Reading
Capsida's Recent Advances in Genetic Medicine Capsida Biotherapeutics has made a remarkable stride by partnering with AbbVie to combat neurodegenerative diseases, a step that marks a significant achievement in the realm of genetic medicine. The collaboration has evolved, leading to AbbVie exercising its option on the first neurodegenerative disease program, which...
Continue Reading
AB Amber Grid's 2024 Operating Results Overview AB Amber Grid has published its unaudited financial results for the year 2024, reflecting the company’s performance in accordance with the International Financial Reporting Standards. With a focus on strategic growth, the company demonstrated robust management despite challenges in the market. Financial Performance...
Continue Reading
Linkage Global Inc. Closes $1 Million Private Placement Financing Linkage Global Inc (NASDAQ: LGCB), a leading cross-border e-commerce service provider based in Japan, has successfully completed a private placement financing that raised $1 million. This announcement marks a significant milestone for the company as it continues to enhance its financial foundation. Details...
Continue Reading
Understanding the Amedisys and UnitedHealth Merger Situation Amedisys Inc (NASDAQ: AMED) has seen its shares rise as the company announces an extension to its merger deadline with UnitedHealth Group Incorporated (NYSE: UNH). This unexpected turn of events has grabbed the attention of investors and industry watchers alike. What Is the Merger About? The proposed merger...
Continue Reading
